Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A. Cork MJ, et al. Among authors: thaci d. Br J Dermatol. 2021 May;184(5):857-870. doi: 10.1111/bjd.19460. Epub 2020 Oct 9. Br J Dermatol. 2021. PMID: 32969489 Free PMC article. Clinical Trial.
Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.
Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T; European Tacrolimus Ointment Study Group. Thaçi D, et al. Br J Dermatol. 2008 Dec;159(6):1348-56. doi: 10.1111/j.1365-2133.2008.08813.x. Epub 2008 Sep 6. Br J Dermatol. 2008. PMID: 18782319 Clinical Trial.
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H. Thaçi D, et al. Br J Dermatol. 2010 Aug;163(2):402-11. doi: 10.1111/j.1365-2133.2010.09791.x. Epub 2010 Apr 2. Br J Dermatol. 2010. PMID: 20377585 Clinical Trial.
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Papp KA, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3. J Eur Acad Dermatol Venereol. 2013. PMID: 23030767 Clinical Trial.
329 results